Form 4 for XYL Xylem Inc.
Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001562180-23-002451 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-03 | 2023-03-02 | XYL | Yarkadas Hayati | SVP, Pres, EU, WI, GLS | S - Sale+OE | $100.43 | -15.9K | 12.1K | -57% | -$1.60M |
| DM | 2023-03-03 | 2023-03-02 | XYL | Yarkadas Hayati | SVP, Pres, EU, WI, GLS | M - OptEx | $74.08 | +11.1K | 23.1K | +93% | +$823.1K |
| D | 2023-03-03 | 2023-03-01 | XYL | Yarkadas Hayati | SVP, Pres, EU, WI, GLS | A - Grant | $0.00 | +4,204 | 17.0K | +33% | $0 |
| D | 2023-03-03 | 2023-03-01 | XYL | Yarkadas Hayati | SVP, Pres, EU, WI, GLS | F - Tax | $101.09 | -102 | 12.8K | -0.8% | -$10.3K |
| DM | 2023-03-03 | 2023-03-02 | XYL | Yarkadas Hayati | SVP, Pres, EU, WI, GLS | M - OptEx | $0.00 | -11.1K | 0 | -100% | $0 |
| D | 2023-03-03 | 2023-03-01 | XYL | Yarkadas Hayati | SVP, Pres, EU, WI, GLS | A - Grant | $101.09 | +14.6K | 14.6K | New | +$1.48M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | S | D | 15,942 | $100.43 | 12,146 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.27 to $100.64, inclusive. The reporting person undertakes to provide to Xylem, Inc., any security holder of Xylem, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth in Footnote 3 to this Form 4. |
| 2 | Common | Common Stock | 2023-03-02 | M | A | 5,035 | $86.79 | 28,088 | D | — | — | |
| 3 | Common | Common Stock | 2023-03-01 | A | A | 4,204 | $0.00 | 16,977 | D | — | — | (F2) Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 1, 2024, March 1, 2025 and March 1, 2026. |
| 4 | Common | Common Stock | 2023-03-01 | F | D | 102 | $101.09 | 12,773 | D | — | — | (F1) Reflects units withheld to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2021 (40) and March 1, 2022 (62) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) |
| 5 | Common | Common Stock | 2023-03-02 | M | A | 6,076 | $63.55 | 23,053 | D | — | — | |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-03-02 | M | D | 5,035 | $0.00 | 0 | D | $86.76 · — to 2032-03-01 | 5,035 Common Stock | (F5) The May 7, 2020 option grant vested in one-third increments on February 27, 2021, February 27, 2022 and February 27, 2023. |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-03-01 | A | A | 14,625 | $101.09 | 14,625 | D | $101.09 · — to 2033-03-01 | 14,625 Common Stock | (F4) Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2024, March 1, 2025 and March 1, 2026. |
| 8 | Derivative | Stock Option (Right to Buy) | 2023-03-02 | M | D | 6,076 | $0.00 | 0 | D | $63.55 · — to 2030-02-27 | 6,076 Common Stock | (F6) The March 1, 2022 option grant vested one-third on March 1, 2023, and will vest one-third on each of March 1, 2024 and March 1, 2025. |